Physician profile
Chaim Abittan
NPI 1972512002
$24,892.57
in general payments reported to CMS, 2019-2025
40 companies · $2,565 in 2025
The $2,565 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,384 · 2020: $1,063 · 2021: $1,905 · 2022: $2,114 · 2023: $13K · 2024: $2,137 · 2025: $2,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $6,546 · Education: $41.09 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,820.00 |
| Food and Beverage | $6,545.70 |
| Education | $41.09 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $10,831.75 | 2023-2025 | Bylvay, Iqirvo |
| Abbvie INC. | $3,869.25 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,719.06 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,424.90 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,228.37 | 2019-2025 | Entyvio, Vpriv, Eohilia |
| Pfizer INC. | $907.56 | 2019-2025 | |
| Celgene Corporation | $608.26 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $584.14 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $523.29 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $370.22 | 2019-2024 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $261.25 | 2019-2025 | Ocaliva |
| Cumberland Pharmaceuticals, INC. | $226.51 | 2019-2022 | |
| Madrigal Pharmaceuticals | $173.60 | 2024-2025 | Resmetirom, Rezdiffra |
| Merck Sharp & Dohme LLC | $167.62 | 2019-2024 | |
| Redhill Biopharma INC. | $167.51 | 2020-2025 | Talicia |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $167.37 | 2019 | |
| Ferring Pharmaceuticals INC. | $166.52 | 2019-2023 | Rebyota |
| Genzyme Corporation | $163.93 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $136.93 | 2023-2025 | Vowst |
| Daiichi Sankyo INC. | $128.01 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $119.53 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $112.46 | 2024-2025 | Vegzelma, Zymfentra |
| Gilead Sciences, INC. | $97.38 | 2019-2021 | |
| Amgen INC. | $85.28 | 2023 | Amjevita, Avsola |
| Ironwood Pharmaceuticals, INC | $81.36 | 2019-2024 | Linzess |
| Shionogi INC | $74.97 | 2019 | |
| Vivus LLC | $72.73 | 2019-2025 | Pancreaze |
| Regeneron Healthcare Solutions, INC. | $54.96 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $52.62 | 2021 | |
| Evoke Pharma, INC. | $41.21 | 2021-2024 | Gimoti |
| Endo Pharmaceuticals INC. | $40.67 | 2019 | |
| Janssen Scientific Affairs, LLC | $35.77 | 2019 | |
| Enterra Medical, INC. | $35.73 | 2023-2025 | |
| Capsovision, INC. | $34.14 | 2024 | Capsocam Plus |
| Intra-Sana Laboratories | $26.71 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Medtronic, INC. | $25.77 | 2021-2024 | Gi Genius |
| Concordia Pharmaceuticals INC. | $25.20 | 2019 | |
| Allergan, INC. | $18.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.11 | 2019 | |
| Ucb, INC. | $15.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaim Abittan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.